Richard B Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1508288/publications.pdf

Version: 2024-02-01

273 papers	30,304 citations	4942 84 h-index	4870 168 g-index
293 all docs	293 docs citations	293 times ranked	26236 citing authors

#	Article	IF	Citations
1	Membrane transporters in drug development. Nature Reviews Drug Discovery, 2010, 9, 215-236.	21.5	2,886
2	Covid-19 in Critically Ill Patients in the Seattle Region â€" Case Series. New England Journal of Medicine, 2020, 382, 2012-2022.	13.9	2,120
3	The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.. Journal of Clinical Investigation, 1998, 101, 289-294.	3.9	931
4	Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clinical Pharmacology and Therapeutics, 2001, 70, 189-199.	2.3	883
5	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical Pharmacology and Therapeutics, 2004, 75, 13-33.	2.3	781
6	SLC transporters as therapeutic targets: emerging opportunities. Nature Reviews Drug Discovery, 2015, 14, 543-560.	21.5	584
7	Polymorphisms in OATP-C. Journal of Biological Chemistry, 2001, 276, 35669-35675.	1.6	558
8	MOLECULARBASIS OFETHNICDIFFERENCES INDRUGDISPOSITION ANDRESPONSE. Annual Review of Pharmacology and Toxicology, 2001, 41, 815-850.	4.2	552
9	Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics. Gastroenterology, 2006, 130, 1793-1806.	0.6	542
10	Fruit juices inhibit organic anion transporting polypeptideâ€"mediated drug uptake to decrease the oral availability of fexofenadine. Clinical Pharmacology and Therapeutics, 2002, 71, 11-20.	2.3	538
11	Genetic Determinants of Response to Warfarin during Initial Anticoagulation. New England Journal of Medicine, 2008, 358, 999-1008.	13.9	516
12	OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metabolism and Disposition, 1999, 27, 866-71.	1.7	468
13	Transporters and drug therapy: Implications for drug disposition and disease. Clinical Pharmacology and Therapeutics, 2005, 78, 260-277.	2.3	425
14	The orphan nuclear receptor HNF4Î± determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nature Medicine, 2003, 9, 220-224.	15.2	418
15	Inhibition of P-Glycoproteinâ€"Mediated Drug Transport. Circulation, 1999, 99, 552-557.	1.6	407
16	Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmaceutical Research, 1999, 16, 408-414.	1.7	404
17	Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans. Clinical Pharmacology and Therapeutics, 2007, 81, 362-370.	2.3	374
18	The Effect of Common Polymorphisms of the Î²2-Adrenergic Receptor on Agonist-Mediated Vascular Desensitization. New England Journal of Medicine, 2001, 345, 1030-1035.	13.9	344

#	Article	IF	Citations
19	Disrupted Bile Acid Homeostasis Reveals an Unexpected Interaction among Nuclear Hormone Receptors, Transporters, and Cytochrome P450. Journal of Biological Chemistry, 2001, 276, 39411-39418.	1.6	343
20	Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metabolism Reviews, 2002, 34, 47-54.	1.5	336
21	Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs. Journal of Clinical Pharmacology, 2007, 47, 566-578.	1.0	328
22	Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2). Journal of Biological Chemistry, 2005, 280, 9610-9617.	1.6	316
23	CYP2C9 allelic variants: ethnic distribution and functional significance. Advanced Drug Delivery Reviews, 2002, 54, 1257-1270.	6.6	309
24	Drug Transporters in Drug Efficacy and Toxicity. Annual Review of Pharmacology and Toxicology, 2012, 52, 249-273.	4.2	308
25	Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 223-228.	1.3	302
26	The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics and Genomics, 2001, 11, 555-572.	5.7	293
27	Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metabolism and Disposition, 2000, 28, 655-60.	1.7	286
28	Identification and Functional Characterization of a New CYP2C9 Variant (CYP2C9*5) Expressed among African Americans. Molecular Pharmacology, 2001, 60, 382-387.	1.0	268
29	Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics, 2004, 5, 243-272.	0.6	261
30	Naringin is a Major and Selective Clinical Inhibitor of Organic Anion-Transporting Polypeptide 1A2 (OATP1A2) in Grapefruit Juice. Clinical Pharmacology and Therapeutics, 2007, 81, 495-502.	2.3	252
31	Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics and Genomics, 2003, 13, 595-606.	5.7	238
32	Pharmacogenetics of Longâ€Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study. Journal of Infectious Diseases, 2005, 192, 1931-1942.	1.9	232
33	Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clinical Pharmacology and Therapeutics, 2003, 73, 41-50.	2.3	223
34	TRANSPORTERS ANDRENALDRUGELIMINATION. Annual Review of Pharmacology and Toxicology, 2004, 44, 137-166.	4.2	210
35	Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study. Clinical Infectious Diseases, 2006, 42, 401-407.	2.9	208
36	Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux Drug Transporter P-glycoprotein. Anesthesiology, 2002, 96, 913-920.	1.3	205

#	Article	IF	Citations
37	Application of Three-Dimensional Quantitative Structure-Activity Relationships of P-Glycoprotein Inhibitors and Substrates. Molecular Pharmacology, 2002, 61, 974-981.	1.0	204
38	P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Research, 1999, 59, 3944-8.	0.4	194
39	Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity. Clinical Pharmacology and Therapeutics, 1994, 56, 359-367.	2.3	191
40	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. Clinical Pharmacology and Therapeutics, 2018, 104, 890-899.	2.3	185
41	Three-Dimensional Quantitative Structure-Activity Relationships of Inhibitors of P-Glycoprotein. Molecular Pharmacology, 2002, 61, 964-973.	1.0	179
42	Effect of Grapefruit Juice Volume on the Reduction of Fexofenadine Bioavailability: Possible Role of Organic Anion Transporting Polypeptides*. Clinical Pharmacology and Therapeutics, 2005, 77, 170-177.	2.3	176
43	Nuclear Receptors and Drug Disposition Gene Regulation. Journal of Pharmaceutical Sciences, 2005, 94, 1169-1186.	1.6	176
44	Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clinical Pharmacology and Therapeutics, 2003, 73, 253-263.	2.3	174
45	Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenetics and Genomics, 2007, 17, 647-656.	0.7	172
46	Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins. Circulation Research, 2010, 106, 297-306.	2.0	171
47	Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. European Journal of Clinical Investigation, 2003, 33, 1-5.	1.7	169
48	Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care. Circulation: Cardiovascular Genetics, 2013, 6, 400-408.	5.1	168
49	Ethnicity-dependent Polymorphism in Na+-taurocholate Cotransporting Polypeptide (SLC10A1) Reveals a Domain Critical for Bile Acid Substrate Recognition. Journal of Biological Chemistry, 2004, 279, 7213-7222.	1.6	167
50	Allelic, genotypic and phenotypic distributions of S-mephenytoin 4???-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics and Genomics, 1999, 9, 539-550.	5.7	164
51	Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban. Canadian Journal of Cardiology, 2013, 29, S24-S33.	0.8	162
52	Defining the Cellular Phenotype of â€œAnkyrin-B Syndromeâ€•Variants. Circulation, 2007, 115, 432-441.	1.6	161
53	Bloodâ^'brain barrier transporters and response to CNS-active drugs. European Journal of Clinical Pharmacology, 2009, 65, 1063-1070.	0.8	161
54	A 12R-lipoxygenase in human skin: Mechanistic evidence, molecular cloning, and expression. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 6744-6749.	3.3	157

#	Article	IF	Citations
55	A common Î²1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to Î²-blockade. Clinical Pharmacology and Therapeutics, 2003, 73, 366-371.	2.3	145
56	Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms*. Clinical Pharmacology and Therapeutics, 1995, 57, 645-655.	2.3	143
57	Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. Kidney International, 2016, 89, 1144-1152.	2.6	139
58	Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clinical Pharmacology and Therapeutics, 2005, 77, 291-301.	2.3	138
59	P-glycoprotein Expression, Localization, and Function in Sandwich-Cultured Primary Rat and Human Hepatocytes: Relevance to the Hepatobiliary Disposition of a Model Opioid Peptide. Pharmaceutical Research, 2004, 21, 1294-1302.	1.7	136
60	Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration. Clinical Infectious Diseases, 2006, 43, 783-786.	2.9	131
61	Induction of Intestinal P-glycoprotein by St John's Wort Reduces the Oral Bioavailability of Talinolol. Clinical Pharmacology and Therapeutics, 2007, 81, 669-678.	2.3	131
62	Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity. Cancer Research, 2008, 68, 4983-4989.	0.4	124
63	Ontogeny of Human Hepatic and Intestinal Transporter Gene Expression during Childhood: Age Matters. Drug Metabolism and Disposition, 2014, 42, 1268-1274.	1.7	124
64	Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A*. Clinical Pharmacology and Therapeutics, 1999, 66, 224-231.	2.3	123
65	Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon Cancer. Cancer Research, 2008, 68, 10315-10323.	0.4	122
66	Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. American Journal of Physiology - Renal Physiology, 2010, 298, F997-F1005.	1.3	122
67	Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenetics and Genomics, 2008, 18, 439-448.	0.7	120
68	Differential Inhibition of Rat and Human Na+-Dependent Taurocholate Cotransporting Polypeptide (NTCP/SLC10A1)by Bosentan: A Mechanism for Species Differences in Hepatotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 1170-1178.	1.3	119
69	Pharmacogenomics of the OATP and OAT families. Pharmacogenomics, 2004, 5, 273-282.	0.6	117
70	Interplay between the Nuclear Receptor Pregnane X Receptor and the Uptake Transporter Organic Anion Transporter Polypeptide 1A2 Selectively Enhances Estrogen Effects in Breast Cancer. Cancer Research, 2008, 68, 9338-9347.	0.4	117
71	Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug Development. Oncologist, 2005, 10, 104-111.	1.9	116
72	Pharmacogenomics of organic anion-transporting polypeptides (OATP). Advanced Drug Delivery Reviews, 2002, 54, 1343-1352.	6.6	111

#	Article	IF	Citations
73	Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and Rifampin. Molecular Pharmacology, 2008, 74, 320-329.	1.0	109
74	Impact of Genetic Variation in OATP Transporters to Drug Disposition and Response. Drug Metabolism and Pharmacokinetics, 2013, 28, 4-18.	1.1	108
75	HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN. Drug Metabolism and Disposition, 2005, 33, 676-682.	1.7	105
76	CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2015, 43, 1484-1490.	1.7	103
77	Pharmacogenomics of MRP Transporters (ABCC1-5) and BCRP (ABCG2). Drug Metabolism Reviews, 2008, 40, 317-354.	1.5	102
78	Molecular Cloning and Functional Expression of a Phorbol Ester-inducible 8S-Lipoxygenase from Mouse Skin. Journal of Biological Chemistry, 1997, 272, 24410-24416.	1.6	101
79	Arg389Gly ??1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics and Genomics, 2001, 11, 191-197.	5.7	100
80	Ritonavir, Saquinavir, and Efavirenz, but Not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1068-1075.	1.3	98
81	Identification of Amino Acid Determinants of the Positional Specificity of Mouse 8S-Lipoxygenase and Human 15S-Lipoxygenase-2. Journal of Biological Chemistry, 2000, 275, 1287-1293.	1.6	94
82	Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity. Clinical Infectious Diseases, 2006, 43, 779-782.	2.9	91
83	Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Molecular Pharmacology, 2000, 57, 24-35.	1.0	90
84	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clinical Pharmacology and Therapeutics, 2006, 79, 186-196.	2.3	87
85	MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics and Genomics, 2002, 12, 425-427.	5.7	84
86	Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. British Journal of Pharmacology, 2003, 139, 1111-1118.	2.7	83
87	Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood, 2011, 118, 3163-3171.	0.6	81
88	The Human Organic Anion Transport Protein SLC21A6 Is Not Sufficient for Bilirubin Transport. Journal of Biological Chemistry, 2003, 278, 20695-20699.	1.6	79
89	Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenetics and Genomics, 2011, 21, 103-114.	0.7	79
90	Transporters and xenobiotic disposition. Toxicology, 2002, 181-182, 291-297.	2.0	78

#	Article	IF	Citations
91	Differential in Vivo Sensitivity to Inhibition of P-glycoprotein Located in Lymphocytes, Testes, and the Blood-Brain Barrier. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 1012-1018.	1.3	78
92	Transporters and Drug Discovery:â€‰ Why, When, and How. Molecular Pharmaceutics, 2006, 3, 26-32.	2.3	77
93	Identification of Amino Acids in Rat Pregnane X Receptor that Determine Species-Specific Activation. Molecular Pharmacology, 2004, 65, 36-44.	1.0	76
94	Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate) Tj ETQq0 0 0 rgBT /Overlock 10 T 291, 1204-9.	1.3	76
95	Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics and Genomics, 1999, 9, 511-6.	5.7	75
96	Transactivation of Rat Apical Sodium-Dependent Bile Acid Transporter and Increased Bile Acid Transport by 1Î±,25-Dihydroxyvitamin D3 via the Vitamin D Receptor. Molecular Pharmacology, 2006, 69, 1913-1923.	1.0	73
97	Human Î²2-adrenergic receptor polymorphisms: No association with essential hypertension in black or white Americans. Clinical Pharmacology and Therapeutics, 2000, 67, 670-675.	2.3	70
98	Liver X receptor Î± and farnesoid X receptor are major transcriptional regulators of OATP1B1. Hepatology, 2010, 52, 1797-1807.	3.6	68
99	A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X Receptor. Drug Metabolism and Disposition, 2008, 36, 500-507.	1.7	67
100	OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. British Journal of Cancer, 2015, 112, 857-865.	2.9	67
101	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2015, 60, 3620-3630.	1.1	66
102	In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. Journal of Pharmacology and Experimental Therapeutics, 1996, 279, 4-11.	1.3	66
103	Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1). Drug Metabolism and Disposition, 2011, 39, 558-562.	1.7	65
104	CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Research and Treatment, 2013, 139, 95-105.	1.1	65
105	DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. Pharmaceutics, 2019, 11, 199.	2.0	65
106	â€œInactiveâ€•excipients such as Cremophor can affect in vivo drug disposition. Clinical Pharmacology and Therapeutics, 2003, 73, 394-396.	2.3	64
107	Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. European Heart Journal, 2012, 33, 2856-2864.	1.0	64
108	Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Therapeutic Drug Monitoring, 2015, 37, 428-436.	1.0	64

#	Article	IF	Citations
109	Trimethylamine-N-oxide. Current Opinion in Lipidology, 2016, 27, 148-154.	1.2	62
110	Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation. PLoS ONE, 2011, 6, e27808.	1.1	62
111	A Common Polymorphism in the Bile Acid Receptor Farnesoid X Receptor Is Associated with Decreased Hepatic Target Gene Expression. Molecular Endocrinology, 2007, 21, 1769-1780.	3.7	61
112	Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenetics and Genomics, 2010, 20, 45-57.	0.7	60
113	HLADQA1*05 genotype predicts antiâ€drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 356-363.	1.9	60
114	Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study. Pharmacogenetics and Genomics, 2006, 16, 837-845.	0.7	59
115	MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 295-298.	0.9	54
116	Î²2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Pharmacogenetics and Genomics, 2004, 14, 517-522.	5.7	54
117	Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Cmaj, 2015, 187, 174-180.	0.9	54
118	Targeted next generation sequencing as a tool for precision medicine. BMC Medical Genomics, 2019, 12, 81.	0.7	54
119	Hepatic OATP1B Transporters and Nuclear Receptors PXR and CAR: Interplay, Regulation of Drug Disposition Genes, and Single Nucleotide Polymorphisms. Molecular Pharmaceutics, 2009, 6, 1644-1661.	2.3	53
120	Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2. Clinical Pharmacology and Therapeutics, 2011, 89, 816-820.	2.3	53
121	Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. Molecular Pharmaceutics, 2017, 14, 310-318.	2.3	53
122	<scp>HLA</scp>â€<scp>DQA</scp>1â€<scp>HLA</scp>â€<scp>DRB</scp>1 polymorphism is a major predictor of azathioprineâ€induced pancreatitis in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 615-620.	1.9	53
123	Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. Canadian Journal of Cardiology, 2017, 33, 1036-1043.	0.8	52
124	Development of A Real-Time in Vivo Transcription Assay: Application Reveals Pregnane X Receptor-Mediated Induction of CYP3A4 by Cancer Chemotherapeutic Agents. Molecular Pharmacology, 2002, 62, 439-445.	1.0	51
125	Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease. American Journal of Gastroenterology, 2014, 109, 994-1004.	0.2	50
126	Genetic polymorphism of (S)-mephenytoin 4â€²-hydroxylation in populations of African descent. British Journal of Clinical Pharmacology, 1999, 48, 402-408.	1.1	49

#	Article	IF	Citations
127	The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a033027.	2.9	49
128	??1A-Adrenergic receptor polymorphism. Pharmacogenetics and Genomics, 1999, 9, 651-656.	5.7	48
129	Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochemical Pharmacology, 2012, 84, 104-112.	2.0	48
130	In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. Pharmacogenetics and Genomics, 2001, 11, 809-814.	5.7	47
131	Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling. Drug Metabolism and Disposition, 2015, 43, 325-334.	1.7	47
132	3-Hydroxy-3-methylglutarylâ€“coenzyme a reductase inhibitors (statins) and genetic variability (single) Tj ETQq0 0 0 rgBT /Overlock 10 T Pharmacology and Therapeutics, 2004, 75, 381-385.	2.3	46
133	St Johnâ€™s wort-associated drug interactions: Short-term inhibition and long-term induction?. Clinical Pharmacology and Therapeutics, 2005, 78, 19-24.	2.3	44
134	The Anthelminthic Agent Albendazole Does Not Interact with P-Glycoprotein. Drug Metabolism and Disposition, 2002, 30, 365-369.	1.7	43
135	Polymorphism Screening in the Cardiac K+ Channel Gene KCNA5*. Clinical Pharmacology and Therapeutics, 2005, 77, 138-144.	2.3	41
136	The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs. American Journal of Physiology - Renal Physiology, 2010, 298, G248-G254.	1.6	41
137	Absence of both <scp>MDR</scp>1 (<scp>ABCB</scp>1) and Breast Cancer Resistance Protein (<scp>ABCG</scp>2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 164-170.	1.2	41
138	Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1. Drug Metabolism and Disposition, 2019, 47, 832-842.	1.7	41
139	Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohnâ€™s disease. Scientific Reports, 2020, 10, 1866.	1.6	40
140	Human MRP3 transporter: identification of the 5â€²-flanking region, genomic organization and alternative splice variants1The GenBank accession numbers of MRP3 and its splice variants MRP3A and MRP3B described in this paper are AF085690, AF085691 and AF085692, respectively.1. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1415, 369-374.	1.4	39
141	Personalized medicine and antiplatelet therapy: ready for prime time?. European Heart Journal, 2009, 30, 1943-1963.	1.0	37
142	Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. Journal of Thrombosis and Thrombolysis, 2020, 49, 294-303.	1.0	37
143	Polymorphisms in Beta-Adrenergic Receptor Genes in the Acquired Long QT Syndrome. Journal of Cardiovascular Electrophysiology, 2002, 13, 252-256.	0.8	36
144	The Organic Cation Transporter, OCTN1, Expressed in the Human Heart, Potentiates Antagonism of the HERG Potassium Channel. Journal of Cardiovascular Pharmacology, 2009, 54, 63-71.	0.8	34

#	Article	IF	Citations
145	The transfer of pravastatin in the dually perfused human placenta. Placenta, 2013, 34, 719-721.	0.7	34
146	A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Advances, 2018, 2, 1935-1945.	2.5	34
147	Beyond CAR and PXR. Current Drug Metabolism, 2005, 6, 385-397.	0.7	33
148	Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance. Molecular Pharmacology, 2017, 91, 14-24.	1.0	33
149	Clinical performance of bleeding risk scores for predicting major and clinically relevant nonâ€major bleeding events in patients receiving warfarin. Journal of Thrombosis and Haemostasis, 2013, 11, 1647-1654.	1.9	32
150	Modulation by Dietary Salt of Verapamil Disposition in Humans. Circulation, 1998, 98, 2702-2708.	1.6	31
151	Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clinical Pharmacology and Therapeutics, 2001, 69, 317-323.	2.3	31
152	Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. Breast Cancer Research and Treatment, 2013, 139, 61-69.	1.1	31
153	Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance. Molecular Cancer Therapeutics, 2015, 14, 994-1003.	1.9	31
154	Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2013, 37, 340-345.	1.9	30
155	Transport Function and Transcriptional Regulation of a Liver-Enriched Human Organic Anion Transporting Polypeptide 2B1 Transcriptional Start Site Variant. Molecular Pharmacology, 2013, 83, 1218-1228.	1.0	29
156	Genetic Determinants of Clozapine-Induced Metabolic Side Effects. Canadian Journal of Psychiatry, 2017, 62, 138-149.	0.9	29
157	Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2). Pharmacogenetics and Genomics, 2011, 21, 506-515.	0.7	28
158	In Vitro and In Vivo Assessment of Renal Drug Transporters in the Disposition of Mesna and Dimesna. Journal of Clinical Pharmacology, 2012, 52, 530-542.	1.0	28
159	The Impact of Obesity on the Pharmacology of Medications Used for Cardiovascular Risk Factor Control. Canadian Journal of Cardiology, 2015, 31, 167-176.	0.8	28
160	Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. Oral Oncology, 2019, 89, 72-78.	0.8	28
161	Modulation of CYP2EI activity by isoniazid in rapid and slow N-acetylators. British Journal of Clinical Pharmacology, 1997, 43, 99-103.	1.1	28
162	Disposition of Atorvastatin, Rosuvastatin, and Simvastatin in Oatp1b2â€/â€•Mice and Intraindividual Variability in Human Subjects. Journal of Clinical Pharmacology, 2012, 52, 1689-1697.	1.0	27

#	Article	IF	Citations
163	Impact of pretreatment dihydropyrimidine dehydrogenase genotypeâ€guided fluoropyrimidine dosing on chemotherapy associated adverse events. Clinical and Translational Science, 2021, 14, 1338-1348.	1.5	27
164	Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. Toxicology and Applied Pharmacology, 2003, 186, 119-126.	1.3	26
165	Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22. Breast Cancer Research and Treatment, 2014, 145, 419-428.	1.1	26
166	Functional characterization of genetic variants in the apical sodiumâ€dependent bile acid transporter (ASBT; SLC10A2). Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1740-1748.	1.4	25
167	Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome <scp>P</scp>450 3<scp>A</scp> Activity and Singleâ€Timeâ€Point Oral Midazolam Microdose Phenotype in Healthy Subjects. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 284-291.	1.2	25
168	Is personalized medicine a dream or a reality?. Critical Reviews in Clinical Laboratory Sciences, 2015, 52, 1-11.	2.7	24
169	$alpha;1A-adrenergic receptor polymorphism and vascular response*1, *2. Clinical Pharmacology and Therapeutics, 2004, 75, 539-545.	2.3	23
170	Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. British Journal of Clinical Pharmacology, 2006, 62, 485-491.	1.1	23
171	Effect of <scp>CYP</scp>4F2,<scp>VKORC</scp>1, and <scp>CYP</scp>2C9 in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	2.3	23
172	Transport of the sulfated, amidated bile acid, sulfolithocholyltaurine, into rat hepatocytes is mediated by Oatp1 and Oatp2. Hepatology, 2002, 35, 1031-1040.	3.6	22
173	Durable Complete Response of Refractory, Progressing Metastatic Melanoma After Treatment with a Patient-Specific Vaccine. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 553-557.	0.7	22
174	A Fibroblast Growth Factor 21â€“Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease. Molecular Pharmacology, 2016, 90, 437-446.	1.0	22
175	Apixaban and RosuvasÂÂtatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2018, 46, 485-492.	1.7	22
176	High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor Î± antagonists. Scientific Reports, 2022, 12, 1185.	1.6	22
177	Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula. British Journal of Pharmacology, 2005, 146, 296-305.	2.7	21
178	Interaction of Three Regiospecific Amino Acid Residues Is Required for OATP1B1 Gain of OATP1B3 Substrate Specificity. Molecular Pharmaceutics, 2012, 9, 986-995.	2.3	21
179	Organic Cation Transporter Variation and Response to Smoking Cessation Therapies. Nicotine and Tobacco Research, 2014, 16, 1638-1646.	1.4	21
180	Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis. Hepatology, 2011, 54, 644-654.	3.6	20

#	Article	IF	Citations
181	CYP3A4 Activity is Markedly Lower in Patients with CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2017, 23, 804-813.	0.9	20
182	Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 149-156.	1.5	20
183	Ciprofloxacin and Rifampin Have Opposite Effects on Levothyroxine Absorption. Thyroid, 2013, 23, 1374-1378.	2.4	19
184	Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation. Journal of the American Geriatrics Society, 2019, 67, 1902-1906.	1.3	19
185	Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. Pharmacogenetics and Genomics, 1994, 4, 162-5.	5.7	18
186	Inability to Upregulate Cytochrome P450 4A and 2C Causes Salt Sensitivity in Young Sprague-Dawley Rats. American Journal of Hypertension, 2006, 19, 1174-1180.	1.0	17
187	Statin Safety in Chinese: A Population-Based Study of Older Adults. PLoS ONE, 2016, 11, e0150990.	1.1	17
188	Identification, Expression, and Functional Characterization of Full-Length and Splice Variants of Murine Organic Anion Transporting Polypeptide 1b2. Molecular Pharmaceutics, 2009, 6, 1790-1797.	2.3	16
189	Crohnâ€™s Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression. Molecular Pharmaceutics, 2019, 16, 4059-4064.	2.3	16
190	Hepatic drug transporters, old and new: Pharmacogenomics, drug response, and clinical relevance. Hepatology, 2009, 50, 1014-1016.	3.6	15
191	Use of Transgenic and Knockout Mouse Models to Assess Solute Carrier Transporter Function. Clinical Pharmacology and Therapeutics, 2011, 89, 612-616.	2.3	15
192	Introduction to Clinical Pharmacology. , 2017, , 365-388.		15
193	Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances. Advanced Drug Delivery Reviews, 2002, 54, 1241-1242.	6.6	14
194	Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort. Pharmacogenetics and Genomics, 2014, 24, 367-369.	0.7	14
195	In Vitro Functional Characterization and in Silico Prediction of Rare Genetic Variation in the Bile Acid and Drug Transporter, Na⁺-Taurocholate Cotransporting Polypeptide (NTCP,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	2.3	14
196	Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of Internal Medicine, 2020, 173, 585-587.	2.0	13
197	Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. Journal of Personalized Medicine, 2017, 7, 20.	1.1	12
198	SLC6A3 Polymorphism Predisposes to Dopamine Overdose in Parkinson's Disease. Frontiers in Neurology, 2018, 9, 693.	1.1	12

#	Article	IF	Citations
199	Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. Clinical Pharmacokinetics, 2019, 58, 1077-1089.	1.6	12
200	Baclofen has a risk of encephalopathy in older adults receiving dialysis. Kidney International, 2020, 98, 979-988.	2.6	12
201	Characterization of the hepatic canalicular membrane transport of a model oligopeptide: ditekiren. Journal of Pharmacology and Experimental Therapeutics, 1997, 281, 297-303.	1.3	12
202	CYP2E1 activity is not altered by influenza vaccination. British Journal of Clinical Pharmacology, 1996, 42, 529-530.	1.1	11
203	Modulation of CYP2EI activity by isoniazid in rapid and slow Nâ€acetylators. British Journal of Clinical Pharmacology, 1997, 43, 99-103.	1.1	10
204	Efficacy and Plasma Drug Concentrations With Nondaily Dosing of Rosuvastatin. Canadian Journal of Cardiology, 2013, 29, 915-919.	0.8	10
205	In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice. Drug Metabolism and Disposition, 2015, 43, 1646-1654.	1.7	10
206	Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFÎ± biologic for ulcerative colitis: a case report. BMC Cancer, 2016, 16, 304.	1.1	10
207	Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas. Histochemistry and Cell Biology, 2017, 148, 345-357.	0.8	10
208	Personalized Anticoagulation: Guided Apixaban Dose Adjustment to Compensate for Pharmacokinetic Abnormalities Related to Short-Bowel Syndrome. Canadian Journal of Cardiology, 2018, 34, 342.e17-342.e19.	0.8	10
209	CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy. Breast Cancer Research and Treatment, 2018, 171, 701-708.	1.1	10
210	Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates. Frontiers in Pharmacology, 2021, 12, 713567.	1.6	10
211	Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?. Journal of Clinical Pharmacology, 2016, 56, S40-58.	1.0	9
212	Food Effect on Rosuvastatin Disposition and Lowâ€Density Lipoprotein Cholesterol. Clinical Pharmacology and Therapeutics, 2018, 104, 525-533.	2.3	9
213	Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Research and Treatment, 2018, 172, 371-379.	1.1	9
214	Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. Breast Cancer Research and Treatment, 2020, 183, 365-372.	1.1	9
215	Site-Directed Mutagenesis Studies on a Putative Fifth Iron Ligand of Mouse 8S-Lipoxygenase: Retention of Catalytic Activity on Mutation of Serine-558 to Asparagine, Histidine, or Alanine. Archives of Biochemistry and Biophysics, 2001, 386, 136-142.	1.4	8
216	Genetic variation in the farnesoid X-receptor predicts Crohnâ€™s disease severity in female patients. Scientific Reports, 2020, 10, 11725.	1.6	8

#	Article	IF	Citations
217	Pharmacogenomicâ€based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system. Clinical and Translational Science, 2021, 14, 2231-2241.	1.5	8
218	Organic Anionâ€“Transporting Polypeptides. , 0, , 75-104.		7
219	Emerging from the Shadows: A Possible Link between Sleep Apnea and Cancer. Journal of Clinical Sleep Medicine, 2014, 10, 363-364.	1.4	7
220	Home- vs. Laboratory-Based Management Of OSA: An Economic Review. Current Sleep Medicine Reports, 2016, 2, 107-113.	0.7	7
221	Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study. Clinical and Translational Gastroenterology, 2021, 12, e00332.	1.3	7
222	Evaluation of herbal products as potential inhibitors of MDR1. Clinical Pharmacology and Therapeutics, 2004, 75, P79.	2.3	6
223	Pharmacogenomics of Drug Transporters. , 0, , 179-213.		5
224	Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. British Journal of Pharmacology, 2010, 161, 1023-1033.	2.7	5
225	Precision Medicine: Lessons Learned From Implementation of a Pharmacogeneticsâ€Based Patient Care Program in a Realâ€World Setting. Clinical Pharmacology and Therapeutics, 2019, 106, 933-935.	2.3	5
226	Transporters and drug disposition. Current Opinion in Drug Discovery & Development, 2000, 3, 94-101.	1.9	5
227	Multiple OATP transporters mediate the cellular uptake of rosuvastatin. Clinical Pharmacology and Therapeutics, 2005, 77, P64-P64.	2.3	4
228	Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 709-722.	1.5	4
229	Incremental Lowering of Low-Density Lipoprotein Cholesterol With Ezetimibe 20 mg vs 10 mg Daily in Patients Receiving Concomitant Statin Therapy. Canadian Journal of Cardiology, 2013, 29, 1395-1399.	0.8	4
230	Pharmacogenetic Advances in Cardiovascular Medicine: Relevance to Personalized Medicine. Current Genetic Medicine Reports, 2013, 1, 1-14.	1.9	4
231	Association of Baclofen With Falls and Fractures in Patients With CKD. American Journal of Kidney Diseases, 2021, 78, 470-473.	2.1	4
232	High affinity uptake by isolated rat hepatocytes of a linear pseudo-hexapeptide, ditekiren. Biochimica Et Biophysica Acta - Biomembranes, 1997, 1328, 41-47.	1.4	3
233	Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights. CJC Open, 2022, 4, 56-64.	0.7	3
234	Drug Transporters. , 2009, , 45-84.		3

#	Article	IF	Citations
235	Duration of Grapefruit Juice Effect on Fexofenadine Interaction. Clinical Pharmacology and Therapeutics, 2003, 73, P48-P48.	2.3	2
236	Identification of nonsynonomous polymorphisms of human organic anion transporting polypeptide-A (OATP-A) associated with altered transport activity. Clinical Pharmacology and Therapeutics, 2004, 75, P93.	2.3	2
237	PI-50OATP1A2 is the major uptake transporter of fexofenadine in humans. Clinical Pharmacology and Therapeutics, 2006, 79, P20-P20.	2.3	2
238	Introduction to Clinical Pharmacology. , 2009, , 321-338.		2
239	Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment. Annals of Internal Medicine, 2021, 174, 432.	2.0	2
240	In-vitro characterization of coding variants with predicted functional implications in the efflux transporter multidrug resistance protein 4 (MRP4, ABCC4). Pharmacogenetics and Genomics, 2021, Publish Ahead of Print, .	0.7	2
241	Pharmacogenetics of Drug Transporters. Drugs and the Pharmaceutical Sciences, 2005, , 109-155.	0.1	2
242	Regulation of Cytochrome P450 3A4 in Nonâ€Alcoholic Fatty Liver Disease by Fibroblast Growth Factor 21. FASEB Journal, 2013, 27, lb537.	0.2	2
243	PI-32The effects of folate supplementation on human CYP2C9 transactivation. Clinical Pharmacology and Therapeutics, 2006, 79, P15-P15.	2.3	1
244	PIII-26Hepatic nuclear factor (HNF)1Î±activates the induction of human CYP2C9 by rifampin (Rif) and interacts with HNF4Î± and small heterodimer partner 1 (SHP-1). Clinical Pharmacology and Therapeutics, 2006, 79, P65-P65.	2.3	1
245	Statin therapy: time for a precision medicine approach?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 187-192.	0.4	1
246	Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1728-1739.	2.2	1
247	Pharmacokinetics of a onceâ€daily tacrolimus formulation in first nations and caucasian liver transplant recipients. Transplant International, 2021, 34, 2266-2273.	0.8	1
248	Mouse NTCPâ€“Mediated Rosuvastatin Uptake In Vitro and in Slc10a1-Deficient Mice. AAPS Journal, 2021, 23, 17.	2.2	1
249	Allelic, genotypic and phenotypic distributions of S-mephenytoin 4???-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics and Genomics, 1999, 9, 539-550.	0.7	1
250	Near Miss or Standard of Care? DPYD Screening for Cancer Patients Receiving Fluorouracil. Current Oncology, 2021, 28, 94-97.	0.9	1
251	Letter: genetic variation in the HLAâ€ÐQA1*05 allele predicts tumour necrosis factorâ€Î± antagonist immunogenicity â€“ does location matter?. Alimentary Pharmacology and Therapeutics, 2021, 53, 1055-1056.	1.9	1
252	Drug efflux transporters and antiviral drug therapy. Expert Opinion on Therapeutic Targets, 2000, 4, 439-446.	1.0	0

#	Article	IF	Citations
253	Stable and tightly regulated expression of human NA+ taurocholate cotransporting polypeptide (NTCP) using a tetracycline-inducible system.. Clinical Pharmacology and Therapeutics, 2003, 73, P13-P13.	2.3	0
254	Identification of a new beta1-adrenergic receptor variant VAL5ALA more frequent in African-Americans.. Clinical Pharmacology and Therapeutics, 2003, 73, P97-P97.	2.3	0
255	Evaluation of ethnicity, gender, and OATP-C genotypes as determinants of pravastatin disposition. Clinical Pharmacology and Therapeutics, 2004, 75, P66.	2.3	0
256	A common polymorphism in the adenylyl cyclase type 9 (AC9) gene does not alter vascular responses to isoproterenol. Clinical Pharmacology and Therapeutics, 2004, 75, P70.	2.3	0
257	Grapefruit juice ingestion reduces talinolol serum concentration. Clinical Pharmacology and Therapeutics, 2005, 77, P4-P4.	2.3	0
258	Effects of infant formula, cow milk and human milk on drug metabolizing enzymes. Clinical Pharmacology and Therapeutics, 2005, 77, P46-P46.	2.3	0
259	OII-B-1The role of NA+-taurocholate cotransporting polypeptide (NTCP) in the hepatic uptake of rosuvastatin. Clinical Pharmacology and Therapeutics, 2006, 79, P5-P5.	2.3	0
260	The Relevance of Transporters in Determining Drug Disposition. , 2006, , 423-459.		0
261	Sunny outlook for personalized medicine: tamoxifen and beyond. Pharmacogenomics, 2013, 14, 1533-1536.	0.6	0
262	Unintended Consequences of Therapy in the Intensive Care Unit. JAMA Internal Medicine, 2014, 174, 574.	2.6	0
263	Solute Carriers. Cancer Drug Discovery and Development, 2014, , 401-442.	0.2	0
264	Personalized medicine: importance of clinical interpretative skills for real-world patient care. Personalized Medicine, 2014, 11, 395-408.	0.8	0
265	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. American Journal of Gastroenterology, 2015, 110, S773.	0.2	0
266	Letter: predicting azathioprineâ€associated pancreatitis in <scp>IBD</scp>â€”phenotype or genotype? Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1044-1045.	1.9	0
267	Letter: immunogenicity of infliximabâ€”ready for routine prediction? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 813-814.	1.9	0
268	Human MRP2 polymorphisms and their impact on substrate transport. FASEB Journal, 2008, 22, 1132.4.	0.2	0
269	Expression and functional characterization of murine organic anion transporting polypeptide 1b2 (oatp1b2/oatp4/lstâ€1). FASEB Journal, 2008, 22, 1132.5.	0.2	0
270	Genetic and clinical determinants of CYP3A4 activity in patients using 4Î²â€hydroxycholesterol as an in vivo probe. FASEB Journal, 2013, 27, 672.3.	0.2	0

#	Article	IF	Citations
271	Application of a genomicsâ€guided warfarin dosing nomogram for hospitalized patients. FASEB Journal, 2013, 27, 673.1.	0.2	0
272	Correspondence: Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1*05 Carriage is Associated with Anti-Drug Antibody Formation in Patients with Inflammatory Bowel Disease â€“ Is HLADQA1*05 gone before itâ€™s here?. Gastroenterology, 2022, , .	0.6	0
273	Nuclear Receptors and Drugâ€“Drug Interactions with Prescription and Herbal Medicines. , 0, , 211-239.		0